Recently, the National Healthcare Security Administration released the "Drugs with a large number of enterprises that have passed the consistency evaluation and have not yet been included in the national centralized procurement". The list involves a total of 151 varieties, with the number of reference preparations and enterprises that have passed consistency evaluation ranging from 5 to 43.
From the final selected varieties, the products included in the national organized drug procurement are mainly those that are clinically mature and have sufficient market competition - varieties that have been on the market for many years, have passed the patent protection period, and are produced by multiple enterprises.
On February 10th, the National Healthcare Security Administration issued the "List of Key Tasks for Efficient Completion of One Thing in the Healthcare Security Field in 2026". The key tasks for 2026 include carrying out at least one batch of centralized and quantity based procurement of national organized drugs and high-value medical consumables in 2026; The National Medical Security Conference to be held at the end of 2025 also clearly stated in arranging the 2026 medical insurance work that a new batch of national organized drug procurement should be carried out.
In addition, it is worth noting that the 2026 Government Work Report, after the first explicit mention of optimizing the policy of centralized drug procurement in the 2025 Government Work Report, once again requires the optimization of centralized drug procurement and price governance.
